Hedge Funds Scorned by MBAs
An increasing number of business school students are aspiring to private equity jobs, while few seek out roles at hedge funds.
News
Pension Tensions Mount Ahead of Brexit Vote
What industry polls are saying about the potential for—and impact of—the UK leaving the EU after Thursday’s referendum.
Rhode Island Pension CIO Departs
Anne-Marie Fink is leaving the $8 billion Employees’ Retirement System of Rhode Island for a multi-family office.
‘Once and For All’: Asset Managers Take on Diversity
The Investment Association and other leading industry representatives want to harmonize national efforts to improve diversity in asset management.
Cambridge Endowment Warns its Managers on Carbon Risk
Engagement trumps divestment for the $8.7 billion British university fund.
CalPERS Names Operations Deputy as Interim CEO
The $291 billion fund expects to have a permanent leader within weeks.
Deloitte Buys Consultant Casey Quirk
The asset-management consultancy, formerly independently owned, will rebrand as Casey Quirk by Deloitte.
300 Club Appoints Chair
Stefan Dunatov becomes the first asset-owner CIO to lead the industry think tank.
Orange County Pension Seeks ‘Second Opinion’ Consultant
A doozy of an RFP awaits risk specialists interested in working alongside Meketa.
‘Multi-Asset’ Means Overcharging for Beta, Says Consultant
Multi-asset managers have actually harmed performance via tactical asset allocation decisions, finds Willis Towers Watson.
BP Investment Chief Quits
John Bearman is leaving the UK pension fund after less than four years, CIO has learned.
Scott Malpass Appointed TIFF Chair
The University of Notre Dame’s long-serving CIO will lead the $9.5 billion fund’s board of directors.
Europe’s Asset Management Crunch
Providers have suffered from their clients’ de-risking and insourcing, research shows.
UBS Builds Out Hedge Fund Manager
O’Connor has added seven portfolio managers from Point72, GLG, and Citadel to its roster.
Visium Managers Charged in Major Insider-Trading Case
The $7 billion hedge fund traded on private drug approval info, the SEC alleges.